key: cord-0805829-k9xd3kso authors: Sartaj Sohrab, Sayed; Aly El-Kafrawy, Sherif; Ibraheem Azhar, Esam title: In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells date: 2022-04-26 journal: J King Saud Univ Sci DOI: 10.1016/j.jksus.2022.102049 sha: e54cd3b18f46f814d579c88be220a5d7061f8fb7 doc_id: 805829 cord_uid: k9xd3kso OBJECTIVE: The acute cases of pneumonia (COVID-19) were first reported from China in December 2019, and the pathogen was identified as SARS-CoV-2. Currently, many vaccines have been developed against this virus by using multiple genes, applying different platforms, and used for the vaccinations of the human population. Spike protein genes play an important role in host cell attachment and viral entry and have been extensively used for the development of vaccine and antiviral therapeutics. Short interfering RNA is also known as silencing RNA and contribute a significant role to regulate the expression of a specific gene. By using this technology, virus inhibition has been demonstrated against many viral diseases. METHODS: In this work, we have reported the Insilico prediction, designing, and experimental validation of siRNAs antiviral potency against SARS-CoV-2-S-RBD. The siDirect 2.0 was selected for siRNAs prediction, and secondary structure was predicted by RNAfold while the HNADOCK was used for molecular docking analysis and specific binding of siRNAs to the selected target. We have used and evaluated four siRNAs for cellular toxicity and determination of antiviral efficiency based on the Ct value of q-real-time PCR in Vero E6 cells. RESULTS: Based on the experimental evaluation and analysis of results from generated data, we observed that there is no cytotoxicity for any tested siRNAs in Vero E6 cells. Total four siRNA were filtered out from twenty-one siRNAs following the strict selection and scoring criteria. The better antiviral efficiency was observed in 3rd siRNAs based on the Ct value of q-real-time PCR. The results that emerged from this study encouraged us to validate the efficiency of these siRNAs in multiple cells by using alone and in a combination of two or more siRNAs to inhibit the SARS-CoV-2 proliferation. CONCLUSION: The Insilico prediction, molecular docking analysis provided the selection of better siRNAs. Based on the experimental evaluation only 3rd siRNA was found to be more effective than others and showed better antiviral efficiency. These siRNAs should also be evaluated in other cell lines either separately or in combination against SARS-CoV-2 to determine their antiviral efficiency. An outbreak of unusual pneumonia was observed in hospitalized patients from Wuhan, China caused by a novel coronavirus in late December 2019. The clinical symptoms varied from asymptomatic infection to severe acute respiratory syndrome (SARS). Currently, this virus has spread to 222 countries and territories with 270,440,970 cases, 5,322,447 and 241,182,700 recoveries (https://www.worldometers.info/coronavirus/last accessed on 13.12.2021, 06:51 the disease was finally designated as COVID-19 in February 2020, and pandemic was declared on March 11, 2020 (WHO,2020b) . This virus falls into the family Coronaviridae, with a +ssRNA virus and the genome size is 26 to 32 kb. Acute respiratory distress syndrome (ARDS) induced by viral pneumonia is attributed to the mortality caused by COVID-19 infections. ARDS represents the most serious complication of SARS-CoV-2 infection with a mortality rate (Azoulay et al., 2020) . Till now, multiple genetic variants have been emerged from different geographic locations and spread globally to infect the human population including recently emerged and known as Omicron. The management and treatment guidelines mainly focused on vaccination, prevention, control, and supportive intensive care involving oxygen supplementation and mechanical ventilation as required (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). Currently, many vaccines have been approved by World Health Organization (WHO) and are being used for vaccination of the human population globally, but still, there is no antiviral therapeutics approved by the USFDA available to combat this disease as well for long term protection from this viral infection. A promising approach for the development of highly specific antiviral therapy can be adopted by using an RNA interference (RNAi) mechanism to regulate the expression of desired genes by degrading the corresponding mRNAs. The use of short interfering RNAs (siRNAs) has been proven as significant oligonucleotide-based therapy against many viral diseases (Sohrab et al., 2018 , Sohrab et al., 2020 Uludag et al., 2020; Donia and Bokhari 2021) . The basic criteria for designing and selecting the potential siRNAs have been described and published (Sohrab et al., 2018) . Currently, more than 20 clinical trials are running to evaluate the RNAi-based biopharmaceuticals for oligonucleotide-based therapeutics (Alnylam, 2020). reports discussed only the prediction and designing of potential siRNAs, except only one report has discussed the designing and experimental evaluation of a few siRNAs against SARS-CoV-2 and found significant antiviral efficacy in Vero cells (Niktab et al., 2021) . So, based on the status and urgent requirement, we report here about the Insilico prediction, designing, molecular docking, cytotoxicity, and experimental validation of siRNAs in Vero E6 cells against SARS-CoV-2. The different concentrations of siRNAs were delivered to Vero E6 cells by Lipofectamine-2000 (Invitrogen, USA) , and the Multiplicity of infection (MOI) 0.1of the virus was used to infect the Vero E6 cells. The purification of viral RNA was done from the lysed cells and subjected to quantitative real-time PCR for the determination of viral load reduction based on Ct value. The data generated and analyzed results showed that only 3rd siRNAs showed the significant and better antiviral activity in tested cells. The Spike protein gene sequence of an isolate from Saudi Arabia, SARS-CoV-2/human/SAU/85791C/2020 genome (GenBank: MT630432.1) was retrieved from NCBI-PubMed. The receptor-binding domain (RBD-S) sequences were used to predict and design the siRNA by using the online tool siDirect version 2.0 (http://siDirect2.RNAi.jp/) (Naito et al., 2009) . To reduce any off-target effect, the maximum T m value was fixed to 21.5°C for seed target duplex stability. The predicted siRNAs were further screened by using the National Centre for Biotechnology Information (NCBI-PubMed) human genomic and transcript database against any similarities with Homo sapiens sequences, and siRNAs with any off-target sequences were eliminated. Generally, to predict and screen the highly potential siRNAs, strict criteria should be followed such as the guide strand should contain A/U at 5′ terminus with a minimum of 4 A/U in the seven base pairs, while G/C should be in passenger strands at 5′ terminus. The minimum T m value for both guide and passenger strands with a smaller number of off-target sequences should be considered for the best siRNAs selection. The software resulted in twenty-one siRNA, but we selected only four siRNAs following the criteria of selection with threshold and algorithm scores (Naito et al., 2009; Sohrab et al.,2018) . The RNAfold 2.4.18 server (http://rna.tbi.univie.ac.at) was used to predict the siRNAs secondary structure. The sequences of the guide strand and passenger strand were exported to software and the program was run to generate the secondary structure. The secondary structure was visualized and downloaded in forna format. The software generated the secondary structure of each siRNAs with minimum free energy (MFE). The MFE of each siRNAs were variable. Based on the current studies, the secondary structure of siRNAs plays a significant role in the efficient binding of target sequences and silencing efficiency. We perform the molecular docking analysis using online HNADOCK software (http://huanglab.phys.hust.edu.cn/hnadock/) to determine the efficient binding affinity of predicted siRNAs with the target region of RBD-S gene sequences (He et al., 2019) . The docked images were visualized in PyMOL 2.5.2 online software (https://pymol.org/2/). The SARS-CoV-2-RBD-S gene sequence and the guide and passenger strand sequences of predicted siRNAs were used as input to evaluate the binding affinity with the target sequences. Based on the lowest T m value for the guide strand and with the least number of passenger strand and the highest binding score of SARS-CoV-2-RBD-S gene sequences off-targets were considered during docking analysis. Based on the online software using siRNA Direct 2.0, HNADOCK for molecular docking analysis, secondary structure prediction, we have selected the four most potential siRNAs for chemical synthesis and further used them for experimental validation of SARS-CoV-2 inhibition in Vero E6 cells. The delivery of siRNAs to Vero E6 cells (ATCC# CRL-1586) was performed through the reverse transfection using a standardized and published protocol (Sohrab et al., 2020; Sohrab et al., 2021b) . The cells were propagated in DMEM media at 37°C and transfected at 60-80% confluency. The different concentrations of siRNAs (0.1-50 nM) were made with a lipid complex by using the Lipofectamine-2000 (Invitrogen, USA). The lipid complex was delivered slowly to the grown Vero E6 cells. All the experiments were performed in triplicates with proper negative and positive controls. The MTT assay was used to determine the cytotoxicity after 72 hours post-transfection. The cytotoxicity of siRNAs in Vero E6 cells was evaluated by Vybrant™ MTT Cell Proliferation Assay Kit as per instructions (ThermoFisher Scientific) as well as by using the published protocol (Sohrab et al., 2020; Sherif Aly El-Kafrawy et al., 2021) . The cells were replenished with fresh DMEM media following the addition of 12 mM-MTT (10 l) and incubated at 37°C for 4 hours. The OD value was measured at 570 nm using the SpectraMax i3x imaging cytometer. The mean OD value was used for the calculation and determination of cytotoxicity by using the standard formula. Corrected absorbance: % cytotoxicity = (100 x (control -sample)). The Vero E6 cells were propagated in DMEM media using 96-well plates and transfected at 90-95% confluency. The SARS-CoV-2 replicates very efficiently in Vero E6 cells and enables achieving the high virus titers in these cells (Ogando et al., 2020 humidified incubator at 5% CO2 and 37°C until 80%-90% of cells showed a cytopathic effect (CPE). After full CPE, the cells were harvested by centrifugation at 500X g for 5 minutes and used for viral RNA isolation and purification. The purification of viral RNA was performed by using QIAampViral RNA Mini Kit (Qiagen) following the manufacturer instructions and subjected for q-real-time PCR by using PowerCheck SARS-CoV-2 real-time-PCR kit (Kogenebiotech-Korea) following the kit protocol. Briefly, the total volume of PCR mixture was made up to 20 l containing 10 l 2X RT-PCR master mix, 5 l primer/probe mix, and 5 l template viral RNA. The results based on the Ct value were interpreted as per kit instructions. The positive results should have the Ct value ≤ 37 and the negative sample should have Ct value > 37 or not detected. The RBD-S protein gene sequence of an isolate from Saudi Arabia, SARS-CoV-2/human/SAU/85791C/2020 was retrieved from NCBI-PubMed used for siRNAs prediction, designing, and selection. The online software siDirect 2.0 predicted twenty-one siRNAs, but only four siRNAs were selected for further analysis as per their specific characteristics and strict selection criteria. The details and the sequences of siRNAs (guide/passenger strand) have been provided in table 1. In this study, we have used the online software RNAfold 2.4.18 for secondary structure prediction for all four siRNA (Fig. 1) . The results have been computed using an online program and the secondary structure of each siRNAs was visualized and downloaded into forna format with MFE structure drawing encoding base-pair probabilities. The structure is colored by base-pairing probabilities. Results of all siRNAs with the MFE are given in table 1. The structures did not show any complexity. The predicted and designed siRNAs were used further for molecular docking analysis to reveal the binding efficiency to the target sequences. We have selected the best siRNAs model from the top ten docked models generated and visualized in PyMOL 2.5.2 from siRNAs and target sequence. The results showed high binding energy of siRNAs guide strand with SARS-CoV-2-RBD-S sequences which ranged from -192.64 to -290.50 kcal/mol. The RMSD score of each siRNAs ranged from 134.02-581.31 Angstrom (Å) (Fig. 2, Table 1 ). The siRNA guide strand showed high sequences complementarity with the target strand and promoted effective binding to the nucleotide bases. In docking analysis, the highest binding affinity was observed with the 3rd siRNA with the score of -290.50 kcal/mol thereby confirming the high structural affinity of this siRNA for the SARS-CoV-2-RBD-S sequence. Additionally, each offtarget corresponding to the 3 rd siRNA passenger strand showed only 2 mismatches at the 5′ end which reduces the possibility of binding to the undesired target and reduces the off-target effect. The present docking analysis showed that the potent siRNAs can efficiently bind with the target sequences of SARS-CoV-2 and can silence the activity of a specific target and thereby hamper the attachment of the virus to host cells. The cytotoxicity results of all the four tested siRNAs were determined and there was no significant cytotoxicity observed in any tested siRNAs in Vero E6 cells ranged from 0.1-50 nM concentrations. The OD and CC-50 values of each siRNAs have been presented in table 2 and fig. 3 . The cells were harvested for viral RNA purification from siRNAs transfected cells after full CPE in positive control using Kit. The purified RNA was subjected to quantitative real-time PCR. The Ct value of each siRNAs was used for determining the viral load in Vero E6 cells. The dose-dependent inhibition and reduction of viral load were observed. The less viral load was observed in 3 rd siRNA than others at 5.0 nM and 10 nM respectively. The Ct value and analyzed results for all four siRNAs have been provided in table 3 fig. 4 . Coronavirus Disease 2019 was caused by SARS-CoV) and based on the genomic sequence similarity with Bat-Coronaviruses, this virus was finally designated as SARS-CoV-2. As of 12.12.2021, this virus has spread to 222 countries and territories with 5,322,447 deaths (06:51 GMT). This virus particularly damages the pulmonary system and lungs tissues, resulting in the malfunctioning of respiratory functions and the death of infected individuals. At the onset of the pandemic, there were no USFDA drugs, antivirals, and approved vaccines, and there was an urgent need to develop effective antiviral therapeutics against SARS-CoV-2. Currently, there are many vaccines have been approved and is used to vaccinate the human population against SARS-CoV-2. But there are still many antiviral drugs, therapeutic molecules including oligonucleotide-based therapeutics are under the stage of an investigation. The RNAi approach is being used to regulate the silencing of a particular gene/target by using siRNA/shRNA molecules. The potential efficiency of a siRNA is determined and evaluated by the availability and binding of target sites as well as the degree of its potentiality. So, the target accessibility of each siRNAs and its binding to the target is crucial for efficient gene silencing (Gatta et al., 2018) . The RNAi technology has played a significant role and produced considerable results towards different diseases caused by various viruses (Jeang, 2012; Chakraborty et al., 2017) . Currently, using RNAi technology, a significant number of siRNAs/shRNAs have been designed, developed, and experimentally evaluated and showed promising results against many viruses including MERS-CoV and SARS-CoV-2 against the multiple targets of a viral genome (Sohrab et al., 2018; Sohrab et al., 2020; Uludag et al., 2020; Panda et al., 2020; Chen et al., 2020; Sohrab et al., 2021a; Sohrab et al., 2021b; Sherif Aly El-Kafrawy et al., 2021; Khaitov et Education in Saudi Arabia for funding this research work through the project number IFPRC-204-141-2020 and King Abdulaziz University, DSR, Jeddah, Saudi Arabia. Figure 1 : The possible folding and secondary structure prediction of Insilico predicted siRNAs molecules computed using with the online web server (1-4). Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset Designing potential siRNA molecule for the nucleocapsid(N) gene silencing of different SARS-CoV-2 strains of Bangladesh: Computational approach Assay Techniques and Test Development for COVID-19 Diagnosis Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. Molecular therapy Computational identification of small interfering RNA targets in SARS-CoV-2 A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2 RNA interference as a promising treatment against SARS-CoV-2 Strategies for improving the specificity of siRNAs for enhanced therapeutic potential Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies COVID-19 Genomics UK (COG-UK) Consortium SARS-CoV-2 variants, spike mutations and immune escape HNADOCK: a nucleic acid docking server for modeling RNA/DNA-RNA/DNA 3D complex structures A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19 RNAi in the regulation of mammalian viral infections Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation An aptamer/ siRNA Chimera against The SARS-CoV-2: A Dual Therapeutic Strategy for The Virus Neutralizing and RNA Interfering Emerging SARS-CoV-2 variants of concern and potential intervention approaches siDirect 2.0: updated software for designing functional siRNA with reduced seeddependent off-target effect Design of advanced siRNA therapeutics for the treatment of COVID-19 SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2 An in-silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2 Discvering potential candidates of RNAi-based therapy for COVID-19 using computational methods Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2 In vitro inhibitory analysis of rationally designed siRNAs against MERS-CoV replication in Huh7 Cells Designing and evaluation of MERS-CoV siRNAs in HEK-293 Cell line In silico Prediction and Designing of Potential siRNAs to be Used as Antivirals Against SARS-CoV-2 In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape Prospects for RNAi Therapy of COVID-19 Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 Developing effective siRNAs to reduce the expression of key viral genes of COVID Coronavirus disease 2019 (COVID-19): A clinical update The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Declaration of Competing Interest: None declared.